Copyright
©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6069-6081
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6069
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6069
Table 2 Response to treatment
| n | PR (95%CI) | SD (95%CI) | PD (95%CI) | NE (95%CI) | ORR (95%CI) | DCR (95%CI) | |
| Icotinib | 22 | 54.5 (32.2-75.6) | 36.4 (17.2-59.3) | 4.5 (0.1-22.8) | 4.5 (0.1-22.8) | 54.5 (32.2-75.6) | 90.9 (70.8-98.9) |
| Chemotherapy + icotinib | 34 | 44.1 (27.2-62.1) | 52.9 (35.1-70.2) | 2.9 (0.1-15.3) | 44.1 (27.2-62.1) | 97.1 (84.7-99.9) | |
| 2-cycle chemo | 21 | 47.6 (25.7-70.2) | 52.4 (29.8-74.3) | 47.6 (25.7-70.2) | 100.0 (83.9-100.0) | ||
| 2DP | 11 | 36.4 (10.9-69.2) | 63.6 (30.8-89.1) | 36.4 (10.9-69.2) | 100.0 (71.5-100.0) | ||
| 2PP | 10 | 60.0 (26.2-87.8) | 40.0 (12.2-73.8) | 60.0 (26.2-87.8) | 100.0 (69.2-100.0) | ||
| 4-cycle chemo | 13 | 38.5 (13.9-68.4) | 53.8 (25.1-80.8) | 7.7 (0.2-36.0) | 38.5 (13.9-68.4) | 92.3 (64.0-99.8) | |
| 4DP | 4 | 50.0 (6.8-93.2) | 50.0 (6.8-93.2) | 50.0 (6.8-93.2) | 100.0 (39.8-100.0) | ||
| 4PP | 9 | 33.3 (7.5-70.1) | 55.6 (21.2-86.3) | 11.1 (0.3-48.2) | 33.3 (7.5-70.1) | 88.9 (51.8-99.7) | |
| DP | 15 | 40.0 (16.3-67.7) | 60.0 (32.3-83.7) | 40.0 (16.3-67.7) | 100.0 (78.2- 100.0) | ||
| PP | 19 | 47.4 (24.4-71.1) | 47.4 (24.4-71.1) | 5.3 (0.1-26.0) | 47.4 (24.4-71.1) | 94.7 (74.0-99.9) | |
| Total | 56 | 48.2 (34.7-62.0) | 46.4 (33.0-60.3) | 3.6 (0.4-12.3) | 1.8 (0.0-9.6) | 48.2 (34.7-62.0) | 94.6 (85.1-98.9) |
- Citation: Sun SJ, Han JD, Liu W, Wu ZY, Zhao X, Yan X, Jiao SC, Fang J. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World J Clin Cases 2022; 10(18): 6069-6081
- URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6069.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6069